# Ipamorelin FAQ: Risks, Side Effects, and Common Questions Answered

> Ipamorelin FAQ — the risks, the side effects, the CJC-1295 combination, half-life, and FDA status, answered plainly and cited to the published research.

Direct, cited answers to the questions people actually ask about ipamorelin.

## What are the risks of ipamorelin?

The main documented risk is the gap in evidence itself. The only human efficacy trial (NCT00672074, n = 114) failed, and no long-term human safety data exist [3]. Mechanism-based cautions apply to anyone with active cancer, diabetes, or heart disease, and a class-level rat study showed heart-muscle damage with a related ghrelin-receptor agonist [6]. Material from unregulated suppliers adds an unverified-purity risk.

## What are the downsides of ipamorelin?

The biggest downside is that it is unproven where it counts: the one human trial that tested a real outcome missed its endpoint [3]. Other downsides include no approved use anywhere, no long-term safety database, a class-level cardiotoxicity signal in rats [6], tightened compounding access since 2024, and a prohibition in sport. Reported side effects (flushing, hunger, mild puffiness) are minor but real to users.

## Does ipamorelin cause cancer?

No study shows ipamorelin causes cancer, and none has tested the question in humans. The concern is theoretical: growth hormone raises IGF-1, a signal that promotes cell growth [4], so chronically raising GH pulses could in principle feed pre-existing tumors. This is a mechanistic, class-level caution — not an observed finding in any ipamorelin study [1]. Active or recent cancer is listed as a reason for caution for this reason.

## What are the side effects of CJC-1295 and ipamorelin?

Reported side effects of the CJC-1295 + ipamorelin combination are mostly mild and anecdotal: facial flushing soon after injecting, increased hunger, mild water retention, tingling in the hands and feet, injection-site irritation, and occasional early fatigue or dizziness. None come from a controlled human trial of the combination, which has never been run [15]. Ipamorelin's one human trial showed no specific safety signal over seven days [3].

## Does ipamorelin affect cortisol or prolactin?

No — and that is its defining feature. In its founding characterization, ipamorelin released growth hormone potently in rats and pigs (pig ED50 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6) yet did not raise ACTH, cortisol, or prolactin even at doses more than 200 times its GH-active dose [1]. This selectivity is exactly what distinguishes it from older GH-releasing peptides like GHRP-6 and GHRP-2.

## What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that releases growth hormone by activating the ghrelin receptor (GHS-R1a) [1]. It is the most selective growth hormone secretagogue characterized — raising GH without raising cortisol or prolactin [1]. It was developed by Novo Nordisk in the 1990s, has never been approved as a drug, and is sold only as a research chemical.

## What does ipamorelin do for you?

In studies, ipamorelin triggers a pulse of growth hormone through the ghrelin receptor, without raising cortisol or prolactin [1]. In animals it increased longitudinal bone growth in rats [4] and reduced chemotherapy-driven weight loss in ferrets [5]. In the single human efficacy trial it did not speed bowel recovery after surgery [3]. Users anecdotally report better sleep and recovery, but those are not clinical findings.

## What is ipamorelin peptide?

Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, molecular weight about 712 Da — derived from GHRP-1 and engineered with two D-amino acids and a non-natural amino acid (Aib) for stability [1]. It mimics the natural hunger hormone ghrelin at the GHS-R1a receptor to release growth hormone. It is not an endogenous human peptide and has no approved medical use.

## Does ipamorelin reduce belly fat?

No human study has tested ipamorelin for belly fat. In a 2024 ferret study, ipamorelin (1–3 mg/kg) reduced chemotherapy-driven body-weight *loss* by about 24% — the opposite context from fat loss [5]. Some users anecdotally report a gradually leaner look over weeks to months, but that is unverified and confounded by diet and training [13]. There is no controlled evidence that ipamorelin reduces abdominal fat in people.

## Why is ipamorelin being discontinued?

Ipamorelin was never an approved drug to discontinue; its clinical development simply stopped after its only Phase 2 trial (postoperative ileus, n = 114) missed its primary endpoint [3]. Separately, access tightened in 2024 when the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, restricting compounding-pharmacy supply.

## What does CJC-1295 and ipamorelin do?

Together they push growth hormone through two complementary pathways: CJC-1295 (a GHRH analog) amplifies the GH baseline, and ipamorelin (a ghrelin-receptor agonist) adds discrete pulses without raising cortisol [1]. A 2026 review found the combination improved muscle tetanic tension in a mouse muscle-loss model, but stressed the evidence is animal-only [15]. The combination has never been tested in a human trial.

## Does ipamorelin increase IGF-1?

Not always. Growth hormone normally raises liver-made IGF-1, but short rodent ipamorelin studies often show no measurable change: in the 15-day rat bone-growth study, ipamorelin increased bone growth dose-dependently with **no** change in total IGF-1 [4]. This suggests a partly local, GH-pulse-driven effect rather than a sustained systemic IGF-1 rise. Sustained or longer dosing could differ, but that has not been characterized in humans [1].

## How does CJC-1295 ipamorelin work?

The two work through different receptors. CJC-1295 activates the GHRH receptor (a cAMP pathway), raising the underlying GH baseline. Ipamorelin activates the ghrelin receptor GHS-R1a (a calcium pathway), adding a discrete GH pulse without raising cortisol [1]. Because the pathways are separate and complementary, the combination is used to stack a sustained baseline with sharp pulses — though only the single agents, not the pair, have published pharmacology [1].

## How much CJC-1295 ipamorelin should I take?

There is no evidence-based dose, because no peer-reviewed human dosing study of the combination exists. The only combination evidence is an animal muscle-tension result a 2026 review limits to mice [15]. Community subcutaneous "stack" protocols have no controlled-trial basis and are anecdotal, not recommended. This site reports the research record and does not provide a human dose.

## Does CJC-1295 ipamorelin work?

For the combination, there is no human outcome trial. The strongest evidence is a mouse muscle-tension result in a glucocorticoid-induced muscle-loss model, explicitly limited to animals by the 2026 review reporting it [15]. Ipamorelin alone failed its one human efficacy trial [3] but shows real effects in animal bone and weight studies [4] [5]. So: plausible mechanism and supportive animal data, but no proof of human benefit.

## How to reconstitute CJC-1295 ipamorelin 5mg?

Research-supply ipamorelin and CJC-1295 ship as a lyophilized (freeze-dried) powder and are reconstituted with bacteriostatic water for research handling, then generally kept refrigerated because peptides degrade with heat and freeze-thaw. These are general handling notes from the research-supply literature, not a clinical or dosing instruction. Because there is no approved human use, no validated "5 mg" reconstitution-to-dose procedure exists, and circulated community ratios are not study-validated [3].

## How long does ipamorelin stay in your system?

The terminal half-life in humans is about two hours [2]. After roughly four to five half-lives (eight to ten hours), most of a single dose is cleared. The growth-hormone pulse it triggers peaks around 40 minutes after dosing and plays out on its own timeline [2]. For drug testing, note that detection is separate: anti-doping labs can detect GH secretagogues even after the peptide clears [7].

## Does ipamorelin make you hungry?

Some users report it does. Ipamorelin acts on the ghrelin receptor — the same receptor the natural hunger hormone uses — and ghrelin-receptor agonists switch on brain appetite centers in animal studies [14]. Community reports describe an uptick in hunger after dosing, usually milder than with GHRP-6. This is a mechanism-based, class-level expectation rather than a measured human side-effect rate.

## Will I gain weight on ipamorelin?

There is no human weight-change trial for ipamorelin at research-use doses. In animals it has shown both an appetite-promoting, adiposity-increasing signal (in mice, partly independent of GH) [13] and, in a different model, reduced chemotherapy-driven weight loss [5]. Anecdotally, users describe a gradually leaner look, but that is unverified and confounded [13]. The honest answer is that direction of weight change is not established in people [3].

## Does ipamorelin increase appetite?

Mechanistically, yes-leaning. Ipamorelin activates the ghrelin receptor, and ghrelin-receptor agonists induce feeding by activating hypothalamic appetite centers in animal studies [14]. In mice, ipamorelin also increased adiposity and leptin partly independently of growth hormone [13]. Users commonly report increased hunger after dosing, generally milder than with GHRP-6. No controlled human appetite measurement exists at research-use doses.

## What does ipamorelin peptide do?

Ipamorelin peptide releases a pulse of growth hormone by activating the ghrelin receptor GHS-R1a, and does so without raising cortisol or prolactin — its defining selectivity [1]. In animals this drove longitudinal bone growth [4] and reduced cachexia-related weight loss [5]. In its one human efficacy trial it did not speed post-surgery bowel recovery [3]. It has no approved medical use and is sold as a research chemical.

## How long does it take for ipamorelin to work?

Pharmacologically, fast: after dosing, the growth-hormone pulse peaks about 40 minutes later, and the peptide's half-life is roughly two hours [2]. That is the measurable, immediate action. Any longer-term, outcome-level "working" (sleep, recovery, body composition) is anecdotal and reported by users over one to twelve weeks — not established by controlled trials, and not a clinical timeline [3].

---

A tolerability-first console read of the ipamorelin literature — the reported side effects, the water-retention question, and the half-life logged plainly, the single failed human trial and the blank long-term-safety line kept in view; the 'md' names a reading lens, never a clinic, and nothing here is dosed, prescribed, or sold.